OncoteqAG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibody drug conjugate (ADC) TEQ102 from biotech company Tubulis for the treatment of patients with CD30-positive lymphomas, including but not limited to, T-cell and Hodgkin’s lymphomas. Patients with these types of lymphomas and whose disease recur are faced with limited treatment options that have relatively poor long-term outcomes. 

Read more in the attached press release.